Regeneron Pharmaceuticals (REGN) Stock Forecast, Price & News

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

Is Regeneron Pharmaceuticals a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 1 sell rating, 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) released its quarterly earnings data on Wednesday, May, 4th. The biopharmaceutical company reported $11.49 EPS for the quarter, beating analysts' consensus estimates of $9.37 by $2.12. The biopharmaceutical company had revenue of $2.97 billion for the quarter, compared to analysts' expectations of $2.69 billion. Regeneron Pharmaceuticals had a net margin of 48.06% and a trailing twelve-month return on equity of 50.10%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $10.09 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

What price target have analysts set for REGN?

17 analysts have issued 12-month price objectives for Regeneron Pharmaceuticals' shares. Their forecasts range from $575.00 to $844.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $720.11 in the next year. This suggests a possible upside of 3.9% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

• Dr. Leonard S. Schleifer M.D., Ph.D., Founder, Pres, CEO & Director (Age 69, Pay $6.47M)
• Dr. George D. Yancopoulos M.D., Ph.D., Scientific Founder, Pres, Chief Scientific Officer & Director (Age 62, Pay $6.4M) (LinkedIn Profile)
• Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 58, Pay $1.9M) (LinkedIn Profile)
• Mr. Joseph J. LaRosa, Exec. VP, Gen. Counsel & Sec. (Age 63, Pay $1.75M) (LinkedIn Profile)
• Dr. Andrew J. Murphy Ph.D., Exec. VP of Research (Age 63, Pay $1.57M)
• Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 49, Pay $1.77M)
• Ms. Patrice Gilooly, Sr. VP of Quality Assurance & Operations
• Mr. Christopher R. Fenimore, Sr. VP, Head of Accounting & Controller (Age 51) (LinkedIn Profile)
• Mr. Gerald Underwood, Sr. VP of Technical Operations
• Mr. Bob McCowan, Sr. VP of IT & Chief Information Officer

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Exact Sciences (EXAS), Repligen (RGEN), Neurocrine Biosciences (NBIX), Halozyme Therapeutics (HALO), Exelixis (EXEL) and Ionis Pharmaceuticals (IONS).
View all of REGN's competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.83%), Vanguard Group Inc. (7.70%), Capital World Investors (5.48%), State Street Corp (4.72%), Wellington Management Group LLP (2.66%) and Loomis Sayles & Co. L P (2.35%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends for Regeneron Pharmaceuticals.

Which major investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Wellington Management Group LLP, KBC Group NV, Canada Pension Plan Investment Board, Prudential Financial Inc., Loomis Sayles & Co. L P, Retirement Systems of Alabama, and Los Angeles Capital Management LLC. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Bonnie L Bassler, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Capital World Investors, State Street Corp, Vanguard Group Inc., Aaron Wealth Advisors LLC, Dimensional Fund Advisors LP, Pacer Advisors Inc., and Swiss National Bank.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $692.80.

How much money does Regeneron Pharmaceuticals make?

Regeneron Pharmaceuticals has a market capitalization of $75.20 billion and generates $16.07 billion in revenue each year. The biopharmaceutical company earns $8.08 billion in net income (profit) each year or $70.599990 on an earnings per share basis.

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals employs 10,368 workers across the globe.

Does Regeneron Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

When was Regeneron Pharmaceuticals founded?

Regeneron Pharmaceuticals was founded in 1988.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at (914) 847-7000, via email at [email protected], or via fax at 914-347-2113.